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Introduction
Lung cancer is the leading cause of  cancer mortality worldwide (1). KRAS mutations are the most 
common drivers of  lung adenocarcinoma (LUAD), the major subtype of  non–small cell lung cancers 
(NSCLCs) (2). KRAS mutations are associated with poor response to anti-cancer drug treatments (3–5). 
Furthermore, additional genetic alterations often coexisting with oncogenic KRAS, such as inactivating 
mutations in STK11 or KEAP1, enhance the chemoresistant phenotype (6). Mechanistically, chemore-
sistance may be a consequence of: (a) drug inactivation, (b) reduced drug uptake, (c) increased drug 
efflux, or (d) enhanced repair of  treatment-induced DNA lesions by DNA repair mechanisms (7). Sev-
eral mediators have been identified for KRAS-dependent chemoresistance, including the transcription 
Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current 
standard of care for patients with advanced lung adenocarcinoma (LUAD). However, tumor 
progression evolves in most cases. Therefore, predictive biomarkers are needed for better patient 
stratification and for the identification of new therapeutic strategies, including enhancing the 
efficacy of chemotoxic agents. Here, we hypothesized that discoidin domain receptor 1 (DDR1) 
may be both a predictive factor for chemoresistance in patients with LUAD and a potential target 
positively selected in resistant cells. By using biopsies from patients with LUAD, KRAS-mutant 
LUAD cell lines, and in vivo genetically engineered KRAS-driven mouse models, we evaluated 
the role of DDR1 in the context of chemotherapy treatment. We found that DDR1 is upregulated 
during chemotherapy both in vitro and in vivo. Moreover, analysis of a cohort of patients with 
LUAD suggested that high DDR1 levels in pretreatment biopsies correlated with poor response 
to chemotherapy. Additionally, we showed that combining DDR1 inhibition with chemotherapy 
prompted a synergistic therapeutic effect and enhanced cell death of KRAS-mutant tumors in 
vivo. Collectively, this study suggests a potential role for DDR1 as both a predictive and prognostic 
biomarker, potentially improving the chemotherapy response of patients with LUAD.
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factor NRF2 (8) and telomerase activity (9). Potentially druggable vulnerabilities representing new space 
for therapeutic intervention, such as XPO1 (10), also have been identified. Therefore, considering the 
limited efficacy of  chemotherapy in this clinical setting, an urgent need exists for identification of  addi-
tional druggable targets.
The discoidin domain receptors, DDR1 and DDR2, belong to the family of  receptor tyrosine kinases 
and regulate cell proliferation, survival, migration, and differentiation in mammalian tissues by interacting 
with several types of  collagen (11, 12). In different human cancers, such as breast, lung and hepatocellular 
carcinoma, aberrant DDR1 and DDR2 signaling has been observed to be implicated in tumor development 
and cancer progression (13–16). Moreover, DDR1 promotes local invasion and lung colonization through 
STAT3 activity, implicating a role for DDR1 in defining the metastatic niche (17). Notably, DDR1 expres-
sion has been reported to decrease sensitivity to chemotherapy and induce survival signals, which may lead 
to cancer relapse (18–21). Recent studies demonstrated that miR-199a-3p–dependent DDR1 expression 
confers malignant cisplatin resistance phenotype to ovarian cancer (22). Similarly, DDR1 promotes lung 
cancer chemoresistance in a TM4SF1-dependent manner (23). DDR1 has been identified as a component 
of  a 7-gene group of  cancer-associated factors that is maintained after chemotherapy treatment, essential 
for cell line survival, and increased in drug-resistant cancer stem cells (24). This body of  collective evidence 
suggests that DDR1 is involved in the molecular responses associated with resistance to chemotherapy; 
however, a direct relationship between abnormal activity of  DDR1 and lung cancer chemoresistance has 
not yet been described. Here, we found that DDR1 expression correlates with response to platinum-based 
chemotherapy in LUAD. Furthermore, DDR1 inhibition synergistically enhances chemotherapy efficacy in 
KRAS-mutant LUAD in vivo.
Results
DDR1 expression increases upon treatment with genotoxic agents in LUAD cell lines. It has been previously report-
ed that DDR1 expression is enhanced by exposure to DNA-damaging agents in various mammalian 
cell types to convey prosurvival functions (22, 25, 26). However, it is currently unknown whether plati-
num-based chemotherapy, the conventional treatment option for KRAS-mutant LUAD, also elicits a similar 
response resulting in DDR1 upregulation. To evaluate this possibility, we exposed both mouse and human 
KRAS-driven LUAD cell lines to various cisplatin concentrations and exposure times. We used KRasG12V 
LUAD cell lines previously generated in our laboratory (27) together with commercially available human 
counterparts. Interestingly, DDR1 levels increased in a dose- and/or time-dependent fashion as measured 
by both q-PCR and Western blotting to a similar extent than that caused by the classical DNA-damaging 
agent doxorubicin (Figure 1).
DDR1 inactivation in patient-derived xenograft cell lines increases apoptosis and improves the efficacy of  chemo-
therapy. We assessed whether tampering with DDR1 expression concomitantly with chemotherapy could 
improve treatment efficacy. To this end, patient-derived xenograft (PDX) cell lines harboring KRAS muta-
tions (14) were used to test whether DDR1 knockdown could synergize with cisplatin to enhance cell death. 
Two independent shRNA sequences were used to efficiently downregulate DDR1 levels (Figure 2A). When 
grown in 2D conditions, DDR1 knockdown in both PDX cell lines resulted in further sensitization to cis-
platin treatment as illustrated by lower IC50 values and reduced cell numbers (Figure 2, B and C). Similar 
results were obtained in 3D conditions (Figure 2, D and E). Decreased cell numbers could be a direct 
consequence of  apoptotic induction as demonstrated by annexin V/PI detection in dual-treated cells when 
compared with either sh-DDR1 or cisplatin alone (Figure 2F).
Association between DDR1 expression and response to therapy in patients with LUAD. We next evaluated 
whether the increased response to chemotherapy upon DDR1 knockdown observed in vitro could be rel-
evant in a clinical setting. We surveyed the online Kaplan-Meier plotter platform (https://kmplot.com/
analysis/) (28) data sets in search of  potential correlations between DDR1 mRNA levels and response to 
chemotherapy. We next evaluated DDR1 effect on the first progression output after chemotherapy in a 
cohort of  125 NSCLC patients for which gene expression data were available. Using the median cutoff, 
we observed that DDR1 overexpression is prognostic of  significantly (log-rank, P = 8.6 × 10–4) shorter 
survival in this cohort (Figure 3A). To further confirm this analysis, we accessed publicly available data 
from The Cancer Genome Atlas (TCGA) database. We focused our analysis on stage II disease because it 
is a homogeneous patient cohort that is uniformly treated with surgery followed by adjuvant chemother-
apy. Therefore, we hypothesized that any potential contribution of  DDR1 in response to chemotherapy 
3insight.jci.org   https://doi.org/10.1172/jci.insight.137869
R E S E A R C H  A R T I C L E
was more likely to be detected in this group compared with other stages, such as IIIA, in which treatment 
tends to be multimodal and more heterogeneous. To further emphasize the importance of  chemotherapy 
treatment, those patients in the TCGA stage II cohort harboring oncogenic drivers, who could have been 
subjected to targeted treatments, were also excluded from the analysis (see Methods for details). Following 
this rationale, we retained 59 stage II patients with clinical profiles compatible with a combination of  sur-
gery and chemotherapy treatment. We then compared DDR1 expression between the 2 cohorts according 
to their primary response to treatment. As shown in Figure 3B, higher DDR1 levels are associated with dis-
ease progression (Wilcoxon’s test, P < 0.05) as compared with those patients annotated as progression free.
These analyses indicate that either overall DDR1 expression before treatment and/or DDR1 induction 
during chemotherapy may predict the clinical outcome. To test this hypothesis, we used an orthotopic PDX 
model that we previously developed by implanting and expanding patient biopsies directly into the lungs 
of  immunodeficient mice (14). Human biopsies were engrafted in the lungs of  Crl:NU-Foxn1nu mice and 
randomly allocated into 2 cohorts receiving either vehicle or chemotherapy treatment. Mice were sacrificed 
at the completion of  the 4-week protocol, and tumor samples were assessed by immunostaining to detect 
DDR1 expression in situ. As expected, chemotherapy treatment induced tumor shrinkage (data not shown). 
Figure 1. Induction of DDR1 expression in lung adenocarcinoma (LUAD) cell lines following cisplatin treatment. Murine (ChA14.6 and ChA14.9) and 
human (A549 and H460) KRAS-mutant lung adenocarcinoma (LUAD) cell lines were treated with cisplatin (4 and 20 μM) and assessed for DDR1 expres-
sion either by qPCR (A) or by Western blot (B) after 24 or 48 hours as indicated. Extracts from untreated control cells (Untr) were used as controls. 
α-Tubulin was used as loading control. Cells were treated with 1 μM doxorubicin during 24 hours as a positive genotoxic control. (C) Quantification of 3 
independent Western blot experiments normalized to untreated controls as shown in B. Data were analyzed using 1-way ANOVA followed by Dunnett’s 
multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as the mean ± SEM of 3 independent experiments.
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Remarkably, we observed that high DDR1 expressing areas were enriched in the residual tumor mass fol-
lowing treatment (Figure 3C). This observation suggests that DDR1 expression correlates with LUAD per-
sistence following chemotherapy. To reinforce this concept, we took advantage of  a previously reported gene 
signature obtained from tumor-propagating cells (TPCs). This is a chemoresistant population that persists 
after repeated cisplatin treatment, acting as a cell reservoir responsible for disease relapse in mouse LUAD 
(29). Interestingly, DDR1 levels appeared consistently elevated in TPC samples when compared with the 
tumor bulk population (Figure 3D and Supplemental Figure 1; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.137869DS1).
Finally, mRNA and protein material samples were taken from a cohort of  patients with LUAD 
with lymph node metastasis before receiving platinum-based therapy. Following treatment, patients 
were classified as responders or nonresponders based on the disappearance and/or persistence of  their 
lymph node metastases, respectively. We assessed DDR1 expression by q-PCR demonstrating a 3-fold 
increase in DDR1 expression, when evaluated in pretreatment biopsies from nonresponder patients, 
when compared with those that subsequently responded to treatment (Figure 3E). This observation was 
further confirmed by Western blot in 3 patient samples from each cohort. Total DDR1 as well as the 
activating DDR1 Y-792 phosphorylation were elevated in pretreatment biopsies from the nonresponder 
patients (Figure 3F). Together, these results suggest that increased DDR1 activity correlates with poor 
response of  patients with LUAD to chemotherapy and, therefore, could potentially serve as a predictive 
biomarker of  treatment efficacy.
Synergistic effect of  DDR1 inhibition and chemotherapy in KRasG12V-driven lung cancer in vivo. We next veri-
fied the synergistic effect of  DDR1 inhibition and cisplatin in a genetically engineered KRasG12V-inducible 
mouse model. We therefore assessed whether DDR1 inhibition could synergize with cisplatin/paclitaxel 
chemotherapy in inducing cell death, which has previously been reported to be an effective therapeutic 
strategy in endogenous KRAS-driven cancer (13, 14). We chose cisplatin/paclitaxel as an adapted regimen 
of  carboplatin plus paclitaxel, which is a universally accepted regimen in NSCLC (30). Likewise, to phar-
macologically inhibit DDR1 we selected the compound 7rh, which is a well-characterized inhibitor previ-
ously validated for in vivo use (14). The combination of  cisplatin and 7rh enhanced cell death of  murine 
KRasG12V cell lines in vitro when compared with either single treatment alone (Supplemental Figure 2).
Intratracheal infection of  KRasLSLG12Vgeo mice with Cre-recombinase adenoviruses (Ad-Cre) induces the 
expression of  KRasG12V in a limited number of  lung cells upon Cre-mediated recombination of  the floxed 
stop cassette inserted within the KRas locus (31). A subset of  these KRasG12V-expressing cells progress 
to LUAD within 8–10 months. Mice bearing KRasG12V-driven LUAD were randomized and treated with 
either vehicle, the specific DDR1 inhibitor 7rh (32), cisplatin/paclitaxel, or a combination of  7rh+cispla-
tin/paclitaxel (protocol summarized in Figure 4A). Treatment efficacy was evaluated in lung sections by a 
quantification of  the tumor area showing enhanced tumor shrinkage upon combined 7rh/chemotherapy 
when compared with either single treatment alone (Figure 4B). Interestingly, we observed a significant 
increase in apoptosis in tumors treated with the combination therapy in comparison with those subjected 
to individual treatments (Figure 4C). This increase in cell death upon DDR1 inhibition could be attributed 
to reduced cell survival or to a previously undescribed effect of  DDR1 inhibition in DNA repair resulting 
Figure 2. Increased sensitivity to cisplatin in patient-derived xenograft (PDX) lung adenocarcinoma cell lines following DDR1 knockdown. (A) Western 
blot validation of DDR1 knockdown in 2 patient-derived xenograft (PDX) cell lines (2 and 3) treated with 2 independent shRNAs (960 and 1358) against 
DDR1 in parallel with a shRNA control. α-Tubulin was used as loading control. Representative Western blots of 2 independent experiments are shown. (B) 
Comparison of IC50 values upon 72 hours cisplatin treatment between control and DDR1-knocked down PDX cell lines maintained in 2D growth conditions. 
Data are shown as the mean ± SEM of 3 independent experiments. The table shows decreased IC50 values (mean ± SD, n = 3) following DDR1 knockdown. 
(C) Cell number quantification following treatment with the indicated concentrations of cisplatin for 72 hours in control and DDR1-knocked down PDX cell 
lines maintained in 2D growth conditions. Data were analyzed using 2-way ANOVA followed by Bonferroni’s multiple comparison test. **P value < 0.01, 
***P value < 0.001. Data are shown as the mean ± SEM of at least 3 independent experiments. (D) Comparison of IC50 values upon 72 hours cisplatin treat-
ment between control and DDR1-knocked down PDX cell lines maintained in 3D growth conditions. Data are shown as the mean ± SEM of 3 independent 
experiments. The table shows decreased IC50 values (mean ± SD, n = 3) following DDR1 knockdown. (E) Cell number quantification following treatment with 
the indicated concentrations of cisplatin for 72 hours in control and DDR1-knocked down PDX cell lines maintained in 3D growth conditions. All values were 
normalized to their respective untreated controls. Data were analyzed using 2-way ANOVA followed by Bonferroni’s multiple comparison test. *P < 0.05, 
**P < 0.01, ***P < 0.001. Data are shown as the mean ± SEM of at least 3 independent experiments. (F) Quantification of apoptosis following treatment 
with the indicated concentrations of cisplatin for 72 hours in control and DDR1-knocked down PDX cell lines maintained in 2D growth conditions. Data were 
analyzed using 2-way ANOVA followed by Bonferroni’s multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as the mean ± SEM 
of 3 independent experiments. P value ns, nonsignificant.
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in higher DNA-damage burden. To evaluate this possibility, we quantified the presence of  the DNA dam-
age marker phosphorylated γ-Histone H2AX (γH2AX) on tumor sections. Interestingly, quantification of  
γHA2X positive staining was similar in both cisplatin/paclitaxel and 7rh+cisplatin/paclitaxel, indicating 
that the overall levels of  DNA damage induced by cisplatin/paclitaxel in these tumors were not affected 
by DDR1 inhibition. These results indicate that the increased efficacy of  the 7rh+cisplatin/paclitaxel treat-
ment is likely attributed to decreased tumor cell survival as opposed to inefficient DNA repair caused by 
DDR1 inhibition (Figure 4D).
Discussion
First-line therapy for advanced KRAS-mutant LUAD consists of  platinum-based chemotherapy in com-
bination with pembrolizumab or pembrolizumab alone in patients whose tumors have PD-L1 expression 
≥50% (33). In this sense, patients with PD-L1–positive advanced NSCLC harboring KRAS mutations 
and treated with frontline pembrolizumab in the Keynote-042 were more likely to have a higher over-
all response rate and longer progression-free survival and overall survival than patients with KRAS WT 
(34, 35). Patients with advanced LUAD benefited from pembrolizumab combined with carboplatin and 
pemetrexed regardless of  KRAS mutation status (36, 37). Two recent phase I clinical trials (NCT03785249 
and NCT03600883) with direct G12C inhibitors showed promising results in this patient subgroup that 
accounts for approximately one-half  of  KRAS mutant LUAD (38, 39). However, there is an urgent need 
to improve treatment of  KRAS mutant patients, particularly for advanced-stage disease. Although chemo-
therapy plus pembrolizumab has yielded promising results, standard chemotherapy also has a high rate of  
toxicities, and, more important, chemoresistance and relapses invariably occur.
An increasing body of  evidence suggests that DDR1 expression is correlated with poor prognosis in 
different tumor types, including lung (13, 40, 41), is involved in metastatic dissemination (15), and is a 
suitable target for cancer treatment (13, 42, 43). Notably, DDR1 expression has been linked to decreased 
sensitivity to chemotherapy (19, 22) and drug resistance (21, 23, 24); however, in vivo DDR1 involvement 
in KRAS-mutant lung cancer cell persistence upon treatment has not been reported (reviewed in ref. 44).
Our results show a rapid induction of  DDR1 expression upon exposure to cisplatin treatment in both 
murine and human cell lines, suggesting a role for DDR1 in implementing fast adaptive responses to cyto-
toxic agents (Figure 1). Nevertheless, we cannot exclude that preexisting high DDR1-expressing cells could 
possess an intrinsic resistance to chemotherapy, which might select for focal viable tumor areas with high 
DDR1 levels after treatment (Figure 2). Therefore, high DDR1 expression levels in platinum-resistant cells 
could be attributed to either active DDR1 upregulation and/or to selection of  preexisting clones with higher 
DDR1 baseline expression. Intriguingly, we previously identified a subpopulation of  KRasG12V-expressing 
lung cells in vivo that were committed to an aggressive transcriptional signature as an early event following 
mutant KRas expression (14): the top hit in this signature was DDR1. Whether high DDR1 expression is a 
cause or a consequence of  selection of  aggressive KRas-mutant clones in vivo, and whether this is directly 
related to intrinsic resistance to chemotherapy remains to be investigated.
To evaluate a potential direct relationship between DDR1 expression and response to therapy in 
patients with LUAD, we surveyed publicly available gene expression data sets in search of  correlations 
between DDR1 abundance and response to chemotherapy. This was further supported by using mRNA 
and protein material from our own cohort of  LUAD biopsies obtained before platinum-based thera-
py. Together, these analyses supported the notion that higher DDR1 expression and activity in patients 
Figure 3. Lung cancer patients with high DDR1 expression display decreased response to chemotherapy and metastasis-free survival. (A) Kaplan-Meier 
metastasis-free survival estimates according to DDR1 levels in lung cancer patients subjected to chemotherapy. Data were obtained from www.kmplot.
com/lung (28). (B) Clinical response of patients with stage II LUAD from the TCGA database harboring non-druggable oncogenic drivers. Results are plotted 
based on DDR1 levels (y axis) and indicated along the x axis as patients free of recurrence (n = 44) vs. recurrence (n = 15). Wilcoxon’s test was used to ana-
lyze statistical significance. *P < 0.05. (C) Crl:NU-Foxn1nu mice implanted with KRAS-mutant PDX were treated with either vehicle or standard chemother-
apy based on cisplatin (3 mg/kg) and paclitaxel (20 mg/kg) administered i.p. every 5 days for 3 weeks (n = 6). After necropsy, tumor samples were fixed 
and analyzed for DDR1 expression by immunostaining. Clones showing high DDR1 expression are observed in the chemotherapy-treated tumors. Scale bar: 
50 μm. (D) Differential DDR1 expression in chemoresistant tumor propagating cells (TPCs) vs. the tumor bulk population (non-TPC). Gene expression data 
was obtained from GSE46439 (29). Wilcoxon’s test P value is indicated above the box plots. (E and F) Samples from 6 patients with LUAD with lymph node 
metastasis were classified, following treatment, according to the persistence (nonresponders, n = 3) or absence (responders, n = 3) of the initial lymph 
node metastasis. Overall DDR1 expression and the activating phosphorylation (Y-792) were evaluated in these samples by qPCR (E) or by Western blot (F). 
GAPDH was used as loading control. High DDR1 expression shows significant association with poor clinical response. Data were analyzed using unpaired 
Student’s t test. *P < 0.05. Data are shown as the mean ± SEM.
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correlated with poor response to chemotherapy (Figure 3). Furthermore, our results obtained both in 
vitro and in vivo strongly suggest that DDR1 could also be considered as a new predictive biomarker of  
patient response to chemotherapy. Future studies considering paired pre- and posttreatment biopsies are 
warranted to further confirm DDR1 as a predictive biomarker in this clinical setting.
We have found substantial variability in DDR1 expression among patients with LUAD reaching up to 
10-fold difference when comparing low and high patients (Supplemental Figure 3), suggesting that these dif-
ferences could be used to stratify patients before chemotherapy. In this context, DDR1 overexpression was not 
correlated with any particular KRAS oncogenic mutations nor with coexisting alterations in genes known to 
enhance chemoresistance such as STK11 or KEAP1 (data not shown). This indicates that DDR1 might be an 
independent prognostic marker of chemoresistance. Although the orthotopic PDX models used in this study 
are p53-deficient (14), we still detected DDR1 induction upon chemotherapy treatment (Figure 3). In agree-
ment, chemoresistant tumor propagating cells (TPC), which display high levels of DDR1 expression (Figure 
3D and Supplemental Figure 1), were identified in p53-deficient LUAD mouse models (29). Additionally, a 
recent study identified a small subset of genes, including DDR1, which are positively selected upon chemo-
therapy treatment but unrelated to either proliferation or lineage-associated mutations including p53 (24). In 
sum, these findings indicate that p53 status is not correlated with DDR1-dependent response to chemotherapy.
We also believe that the results presented here with endogenous KRas-mutant LUAD are proof  of  
the synergistic effect between DDR1 inhibition and chemotherapy. This combination treatment elicited a 
significant increase in apoptosis in endogenous tumors when compared with either treatment alone (Figure 
4). Recently, DDR1 inhibition in a mouse model of  pancreatic ductal adenocarcinoma increased tumor 
response to standard-of-care chemotherapy regimens (45). Similarly, DDR1 inhibition sensitized glioblas-
toma cells to radio- and chemotherapy resulting in prolonged patient survival (46). Therefore, in addition 
to LUAD, DDR1-associated chemoresistance has been observed in other tumors. Indeed, DDR1, together 
with other genes implicated in extracellular matrix remodeling, define a small group of  cancer-associated 
factors that is maintained after chemotherapy in multiple cancer types. In this context, DDR1 is essential 
for cell line survival and elevated in drug-resistant stem-like cancer cells (24).
To speculate on the applicability of our findings to human tumors, DDR1 inhibition could be achieved 
with dasatinib, an FDA-approved small-molecule tyrosine kinase inhibitor that was initially developed as a 
dual ABL-SRC inhibitor and was later found to also display nanomolar inhibitory activity against DDR1 (47). 
An alternative option could be nilotinib, also FDA-approved and recently shown to reduce colorectal cancer 
invasion and metastasis by inhibiting DDR1 kinase activity (48).
In conclusion, we propose that stratification based on DDR1 expression might identify responsive 
patients to the current standard-of-care treatment combining immune checkpoint inhibitors and chemo-
therapy. Whether DDR1 inhibition might enhance this therapeutic response, resulting in a novel strategy to 
overcome chemoresistance in KRAS-driven patients with LUAD, will require further investigation.
Methods
Cell lines and drug treatments. Murine lung cancer cell lines derived from K-RasLSLG12Vgeo mice (ChA14.6 and 
ChA14.9), human lung cancer cell lines derived from KRAS-mutant PDX (PDX 2 and 3) as previously 
described (14), and human KRAS-mutant lung cancer cell lines (A549 and H460, purchased from ATCC) were 
maintained in DMEM containing 10% FBS. Cells were seeded and activated with 50 μg/mL Collagen IV from 
human placenta (MilliporeSigma, C7521) before adding the corresponding drugs. Cisplatin (MilliporeSigma, 
P4394) and Doxorubicin (Selleckchem, S1208) were dissolved in 0.9% NaCl and DMSO, respectively, and used 
at the indicated concentrations. Cell viability was assessed by MTT proliferation assay (Roche). For 3D growth 
conditions, cells were cultured in ultra-low attachment plates (Corning). For 3D conditions, cell viability was 
Figure 4. Treatment with a DDR1 specific inhibitor enhances the efficacy of chemotherapy (chemo) in endogenous KRasG12V-driven lung 
adenocarcinoma. (A) Schematic representation of the in vivo protocol used in KRasLSLG12Vgeo mice. (B) Tumor area was calculated on sections obtained from 
KRasG12V tumors (n = 3–10 tumors per group) following the indicated treatments. Data were analyzed using 1-way ANOVA followed by Bonferroni’s multiple 
comparison test. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as the mean ± SEM. (C) Left: representative immunostaining of the apoptotic marker 
active caspase-3 (C3A) in sections obtained from KRasG12V tumors (n = 6 mice per group) following the indicated treatments. Scale bar: 50 μm. Right: 
quantification of C3A+ cells. Data were analyzed using 1-way ANOVA followed by Bonferroni’s multiple comparison test. **P < 0.01, ***P < 0.001. Data 
are shown as the mean ± SEM. (D) Left: representative immunostaining of the DNA damage marker phosphorylated γ-Histone H2AX (γH2AX) in sections 
of KRasG12V tumors (n = 6 mice per group) following the indicated treatments. Scale bar: 50 μm. Right: quantification of γH2AX+ cells. Data were analyzed 
using 1-way ANOVA followed by Bonferroni’s multiple comparison test. P value ns, nonsignificant. Data are shown as the mean ± SEM. 
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assessed by CellTiter-Glo luminescent viability assay (Promega). For in vivo treatments, the 7rh inhibitor (32) 
was resuspended in 1% carboxymethyl cellulose, 0.25% Tween 80, and administered daily by oral-gavage at a 
dose of 50 mg/kg. 7rh was provided by Ke Ding (State Key Laboratory of Respiratory Diseases, Guangzhou 
Institutes of Biomedicine and Health, Chinese Academy of Sciences).
Standard chemotherapy based on cisplatin (3 mg/kg) and paclitaxel (20 mg/kg) was administered i.p. 
every 5 days. Control mice were treated with the vehicle following identical procedure. Mice were sacrificed 
within 4–8 hours after the last treatment, and samples were obtained for immunohistochemical analysis.
Mice and patient-derived orthoxenografts. The KRas+/LSLG12Vgeo strain has been previously described (49). 
Crl:NU-Foxn1nu mice were purchased from Charles River. Mice were genotyped by Transnetyx (Cordova). 
Primary tumors were obtained from Bellvitge Hospital (HUB) and Catalan Institute of  Oncology (ICO). 
Tumors were aseptically isolated and placed at room temperature in DMEM supplemented with 10% FBS 
plus 50 U/mL penicillin and 50 mg/mL streptomycin. The tumors were implanted in Crl:NU-Foxn1nu mice 
following previously reported procedures (27).
Tumor induction. Tumors were induced in 8- to 12-week-old mice by single intratracheal Ad-Cre instilla-
tion with 1 × 106 pfu/mouse virus after anesthesia (i.p. injection of  ketamine 75 mg/kg, xylazine 12 mg/kg) 
as previously reported (50). A balanced number of  both male and female mice was used for each experiment.
Antibodies for in vitro studies. The antibodies used for Western blotting included those raised against: 
DDR1 (Cell Signaling, 5583), phospho-DDR1 Y-792 (Cell Signaling, 11994), α-Tubulin (Cell Signaling, 
2144), and GAPDH (MilliporeSigma, G8795).
Immunohistochemistry and digital image quantification. Lung lobes containing either endogenous tumors or 
implanted PDX biopsies were fixed in 10% buffered formalin (MilliporeSigma) and embedded in paraffin. 
Antibodies used for immunostaining included those raised against: DDR1 (Cell Signaling, 5583), Caspase3A 
(R&D Systems, AF835), and phospho-γH2AX (Millipore Sigma, JBW301). Digital images of  IHC-stained 
slides were obtained at 40x magnification (0.12 μm/ pixel) using a whole slide scanner (Mirax scan, Zeiss) 
fitted with a x40/0.95 Plan Apochromat objective lens (Zeiss). For automated image classification and quan-
tification, the main areas were highlighted according to the tumor morphological differences. These image 
areas were used as input parameters for the Axiovision 4.8 pattern recognition training software (Zeiss) and 
analyzed by noise reduction method, threshold, and filter conditions as measurement parameters.
Real-time quantitative PCR. Total cellular RNA (1 μg), extracted by Quick-RNA MiniPrep plus Kit (Zymo 
Research), was reverse-transcribed by random primers using One script cDNA Synthesis Kit (Abm), and 
the reverse transcription reaction was then subjected to PCR amplification using SsoAdvanced Universal 
SYBR Green Supermix (Bio-Rad). PCR signals were recorded on a CFX384 Touch Real-Time PCR System 
(Bio-Rad) and analyzed using the Bio-Rad CFX Manager software. Primer sets included human DDR1-Fwd 
(5′-AAGGGACATTTTGATCCTGCC-3′), human DDR1-Rv (5′-CCTTGGGAAACACCGACCC-3′), 
human HPRT-Fwd (5′-TGACACTGGCAAAACAATGCA-3′), human HPRT-Rv (5′-GGTCCTTTTCAC-
CAGCAAGCT-3′), murine DDR1-Fwd (5′-ATGCTGACATGAAGGGACATTT-3′), murine DDR1-
Rv (5′-GGTGTAGCCTACGAAGGTCCA-3′), murine GAPDH-Fwd (5′-AGGTTGTCTCCTGC-
GACTTCA-3′), and murine GAPDH-Rv (5′-GGTGGTCCAGGGTTTCTTACTC-3′).
DDR1 shRNA-mediated knockdown. For knockdown assays cells were infected using lentiviral par-
ticles obtained using MISSION shRNAs directed against human DDR1, shDDR1 960 (Sigma ref. 
TRCN0000010094), and shDDR1 1358 (Sigma ref. TRCN0000010084). Lentiviral particles expressing a 
Non-Target shRNA vector (MilliporeSigma) were used as a negative control.
Patient cohort. Primary tumors were obtained at Hôpital Arnaud de Villeneuve (Centre Hospitalo-Uni-
versitaire de Montpellier, France) following ethical and legal protection guidelines of  human subjects, 
including informed consent. All patients were diagnosed as LUAD and received at least 3 cycles of  plat-
inum-based chemotherapy. Patient response to treatment was classified as responders or nonresponders, 
depending on the absence and/or persistence of  the initial lymph-node metastasis, respectively.
External data sets— patient selection criteria. Using the online KM plotter database, we evaluated a cohort 
of  125 chemotherapy-treated NSCLC patients, with available data regarding gene-expression and first-pro-
gression survival. Of  the 125 patients, 106 were diagnosed with squamous cell carcinoma and 19 with 
LUAD. Kaplan-Meier analysis was performed splitting DDR1 expression using the median value.
For the analysis of  the TCGA data set, we focused on patients with stage II LUAD because we hypothe-
sized this was the cohort in which the chemotherapy clinical benefit could be more easily measured. Among 
117 stage II LUAD cases with available RNA-Seq data, we first withdrew 41 patients from the study owing 
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to incomplete clinical annotations regarding the primary outcome after treatment. We then removed 17 addi-
tional patients who harbored driver oncogenes for which a targeted treatment might have been available at the 
time of  diagnosis (i.e., EGFR, ALK, ERBB2, MET, ROS1, and RIT1). We analyzed DDR1 expression in the 
remaining 59 stage II patients.
Gene expression analysis. GSE46439 normalized microarray data were retrieved from the GEO data-
base, and the 450 differentially expressed genes identified by the authors were used to compute Spearman’s 
correlation between samples. All replicates generated by the authors were used in the analysis, with the 
exception of  replicate 5 from the non-TPC samples. We discarded this replicate because it showed a high 
correlation with both groups (TPC and non-TPC) as shown in Supplemental Figure 1. DDR1 expression 
distribution was assessed in the 10 remaining samples.
To analyze DDR1 expression in TCGA patients we used the RSEM-normalized RNA-seq data provid-
ed by the TCGA consortium. The difference between groups (responder/nonresponders, Figure 3B, and 
TPC/non-TPC, Figure 3D) has been evaluated by performing a Wilcoxon rank-sum test.
Statistics. All experiments were performed as several independent biological replicates. All results are 
reported as mean ± SD or SEM, as indicated in figure legends. Two group comparisons were performed using 
unpaired 2-tailed Student’s t test. When an experiment required comparisons between more than 2 groups, 
statistical analysis was performed using 1- or 2-way ANOVA depending on the number of  grouping factors. 
Dunnett’s test was applied for simple comparisons, whereas Bonferroni’s tests were used for multiple compar-
isons. A P value less than 0.05 was considered significant. Tumor bearing-mice were randomized before drug 
treatment. No statistical method was used to predetermine sample size.
Study approval. All animal experiments were approved by the Ethical Committee of  the CNIO (no. 
PA61-2010, PA30-2011) and the Bellvitge Biomedical Research Institute (IDIBELL, no. AAALAC-1155) 
and performed in accordance with the guidelines stated in the International Guiding Principles for Bio-
medical Research Involving Animals, developed by the Council for International Organizations of  Medical 
Sciences (CIOMS). Primary tumors were obtained from Bellvitge Hospital (HUB) and Catalan Institute 
of  Oncology (ICO) upon approval by the Ethical Committee (CEIC Bellvitge Hospital no. PR265/13 and 
PR036/14) and Hôpital Arnaud de Villeneuve (Centre Hospitalo-Universitaire de Montpellier, France) 
with approval by the Ethical Committee (Comité de Protection des Personnes Sud Méditerranée I no. 
RO-2016/33) following ethical and legal protection guidelines of  human subjects. Specific informed con-
sent for tumor implantation in mice was obtained from all patients, and the study received the approval of  
the IDIBELL and the Hôpital Arnaud de Villeneuve Ethics Committees.
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